Pramlintide acetate is used as an injectable medication for the management of type 1 and type 2 diabetes mellitus. It is used as an adjunct to insulin therapy to help control blood glucose levels, particularly in patients who have not achieved optimal glycemic control despite intensive insulin treatment.

The compound works by slowing gastric emptying, suppressing glucagon secretion, and reducing appetite through effects on central nervous system signaling. This leads to a reduction in postprandial glucose spikes, allowing for better overall glucose control.

It is especially beneficial in helping reduce HbA1c levels and promoting weight loss or minimizing weight gain, which is a common side effect of insulin therapy. Pramlintide acetate is typically administered before meals and is most effective when used in combination with a balanced diet and regular physical activity.

Its application is primarily in patients who require tighter glycemic control and are capable of closely monitoring their blood sugar due to the increased risk of hypoglycemia, especially when used with insulin.